Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats. 2010

Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
Institute of Materia Medica and Department of Pharmaceutics, College of Pharmacy, Third Military Medical University, Chongqing, China.

Prenatal exposure to inflammation produces offspring that are hypertensive in adulthood. This study explored alterations of the renin-angiotensin system (RAS) during the development of hypertension induced by prenatal exposure to lipopolysaccharide (LPS). In addition, the effects of an inhibitor of the nuclear transcription factor (NF)-kappaB (pyrrolidine dithiocarbamate, PDTC) on this process were assessed. Pregnant rats were randomly divided into four groups (n=8): a control group, an LPS group, a PDTC group and an LPS+PDTC group. The rats in these groups were intraperitoneally administered vehicle, 0.79 mg kg(-1) LPS, 100 mg kg(-1) PDTC or LPS plus PDTC, respectively. LPS was given on the 8th, 10th and 12th days, whereas PDTC was given from the 8th to the 14th day during gestation. At various ages from day 1 to 25 weeks, plasma renin activity, plasma angiotensin II (Ang II) levels, renal function, glomerular number, mRNA expression levels of renal cortex renin and angiotensin-converting enzyme (ACE), the number of Ang II-positive cells and NF-kappaB activation were determined. The results showed that prenatal exposure to LPS resulted in significantly lower glomerular numbers and creatinine clearance rates and higher urinary protein and renal cortex ACE mRNA expression in adult offspring. Prenatal LPS also decreased the renal cortex renin mRNA expression and the number of Ang II-positive cells in offspring at 1 day of age, but these increased at 7, 16 and 25 weeks, whereas the plasma renin activity and Ang II concentration remained unchanged. Simultaneously, PDTC treatment markedly reversed the action of LPS. In conclusion, prenatal exposure to LPS resulted in alteration of the intrarenal RAS and renal damage in adult offspring rats.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011297 Prenatal Exposure Delayed Effects The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH. Delayed Effects, Prenatal Exposure,Late Effects, Prenatal Exposure
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines

Related Publications

Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
January 2017, PloS one,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
May 2014, Zhonghua xin xue guan bing za zhi,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
August 2020, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
January 2020, Internal medicine (Tokyo, Japan),
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
February 2015, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
December 2009, Hypertension research : official journal of the Japanese Society of Hypertension,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
July 1993, Kidney international. Supplement,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
April 2015, Clinical and experimental nephrology,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
April 2009, Molecular and cellular endocrinology,
Xue-Qin Hao, and Hai-Gang Zhang, and Zhi-Bing Yuan, and Dan-Li Yang, and Li-Yun Hao, and Xiao-Hui Li
January 1993, Seminars in nephrology,
Copied contents to your clipboard!